José Pérez

ORCID: 0000-0003-4315-1450
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Metal complexes synthesis and properties
  • Organometallic Complex Synthesis and Catalysis
  • Magnetism in coordination complexes
  • Crystallography and molecular interactions
  • Catalytic Cross-Coupling Reactions
  • Asymmetric Hydrogenation and Catalysis
  • Lanthanide and Transition Metal Complexes
  • Chemistry and Stereochemistry Studies
  • Catalytic C–H Functionalization Methods
  • Metal-Organic Frameworks: Synthesis and Applications
  • Thermal and Kinetic Analysis
  • HER2/EGFR in Cancer Research
  • Analytical Chemistry and Chromatography
  • Organometallic Compounds Synthesis and Characterization
  • Hepatitis Viruses Studies and Epidemiology
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research
  • Ferrocene Chemistry and Applications
  • Crystal structures of chemical compounds
  • Coordination Chemistry and Organometallics
  • Inorganic and Organometallic Chemistry
  • Organic Electronics and Photovoltaics
  • Mathematics, Computing, and Information Processing

Ministry of Public Health and Social Assistance
2025

Universidad Politécnica de Cartagena
2014-2024

Benemérita Universidad Autónoma de Puebla
2024

Regeneron (United States)
2023

Baylor College of Medicine
2022

MedSIR (Spain)
2017-2021

Hospital Quirónsalud Barcelona
2019

Fundación Ramón Domínguez
2019

University of Cartagena
2015-2018

Vall d'Hebron Hospital Universitari
2009-2018

PARP inhibitors are active in tumors with defects DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would result impairment and subsequent sensitization inhibitors. show TNBC cells leads damage, downregulation of BRCA1/2, gain poly-ADP-ribosylation, inhibition. In patient-derived primary tumor xenografts, dual...

10.1158/2159-8290.cd-11-0348 article EN Cancer Discovery 2012-08-23

Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant cells chronic exposure to treatment. Genomewide copy-number variation analyses the resistant compared parental revealed a focal amplification genomic DNA containing cyclin E gene. In cohort 34 + treated trastuzumab-based therapy, found that...

10.1073/pnas.1014835108 article EN Proceedings of the National Academy of Sciences 2011-02-14

The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that refractory to anti-HER2 therapy. hypothesis the suppression of this results sensitization agents. However, combinatorial strategy has not been comprehensively tested models trastuzumab and lapatinib resistance.We analyzed vitro cell viability induction apoptosis five different lines resistant lapatinib. Inhibition HER2/HER3 phosphorylation, PI3K/Akt/mTOR, extracellular signal-regulated kinase (ERK)...

10.1158/1078-0432.ccr-11-2750 article EN Clinical Cancer Research 2012-03-09

Pd(II) and Pt(II) complexes with the anions of model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), 1-methylcytosine (1-MecytH) types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethylamino)methyl)phenyl; L 1-Methy, 1-Meura or 1-Mecyt] [M(dmba)(L)(L')] [L 1-Methy 1-Meura; L' PPh3 (M Pd Pt), DMSO Pt)] have been obtained. Palladium [Pd(C6F5)(N−N)(L)] N−N N,N,N',N'-tetramethylethylenediamine (tmeda), 2,2'-bipyridine (bpy), 4,4'-dimethyl-2,2'-bipyridine (Me2bpy)]...

10.1021/ic060374e article EN Inorganic Chemistry 2006-07-15

Abstract Purpose: The study of the cancer secretome suggests that a fraction intracellular proteome could play unanticipated roles in extracellular space during tumorigenesis. A project aimed at investigating invasive led us to alternative function nuclear protein high mobility group A1 (HMGA1) breast invasion and metastasis. Experimental Design: Antibodies against HMGA1 were tested signaling, adhesion, migration, invasion, metastasis assays using cell lines xenograft models. Fluorescence...

10.1158/1078-0432.ccr-18-0517 article EN Clinical Cancer Research 2018-08-22

Novel dinuclear cyclometallated palladium complexes [{Pd(µ-NCO)(C⁁N)}2], containing asymmetric imidato –NCO– bridging units have been synthesised [C⁁N = 7,8-benzoquinolyl; succinimidate (1c), phthalimidate (2c) or maleimidate (3c)]. The reaction of these complexes, and the previously reported analogous imidate precursors a phenylazophenyl (1a–3a) 2-pyridylphenyl (1b–3b) backbone, with tertiary phosphines provides novel mononuclear N-bonded derivatives general formula [Pd(C⁁N)(imidate)(L)] [L...

10.1039/b413886d article EN Dalton Transactions 2004-01-01

A series of new 7-azaindolyl palladium and platinum complexes have been prepared. The X-ray structure determinations [NBu4][M(C6F5)2(Haza-N7)(aza-N1)]·Haza [M = Pd, Pt; aza 7-azaindolate (lH-pyrrolo[2,3-b]pyridinate)] established for the first time coordination to same metal centre both neutral anionic forms ligand. Theoretical calculations at mPW1B95/aug6-31G**/StRSCecp level show that kinetic thermodynamic arguments support observed H-bonding interaction pyrrolo pyridine moieties...

10.1039/b920854b article EN Dalton Transactions 2010-01-01

Dinuclear palladacyclic complexes [{Pd(C∧N)(μ-NCO)}2] (C∧N = N-phenylbenzaldimine, Phbz) containing asymmetric imidato units (−NCO– succinimidate (succ; 1), phthalimidate (phthal; 2), maleimidate (mal; 3), 2,3-dibromomaleimidate (2,3-diBrmal; 4), glutarimidate (glut; 5)) have been readily prepared by reaction between the di-μ-acetate precursor and cyclic imide ligands in a 1:2 molar ratio. Base treatment of less acidic 2-oxazolidone δ-valerolactame with KOH/MeOH was required to give...

10.1021/om2002443 article EN Organometallics 2011-09-09

Recyclable water-soluble Pd complexes were revealed as excellent catalysts for Suzuki–Miyaura cross-coupling of challenging substrates like the antiviral nucleoside analogue 5-iodo-20-deoxyuridine.

10.1039/c4ra01326c article EN RSC Advances 2014-01-01

A broadly applicable catalyst system consisting of water-soluble Pd–imidate complexes has been enployed for the Suzuki–Miyaura cross-coupling four different nucleosides in water under mild conditions. The efficient nature also allowed its application developing a microwave-assisted protocol with purpose expediting catalytic reaction. Preliminary mechanistic studies, assisted by poison tests and stoichiometric performed using an electrospray ionization spectrometer, revealed possible presence...

10.1021/acs.joc.5b02475 article EN The Journal of Organic Chemistry 2016-02-27

Introduction Despite the substantial improvements made in human epidermal growth factor receptor 2 (HER2)–targeted therapies since approval of trastuzumab more than 20 years ago, there is still considerable unmet need patients with HER2-expressing breast cancer (BC) and other solid tumors. Trastuzumab deruxtecan (T-DXd) a newer antibody-drug conjugate approved for treatment metastatic gastric (GC) under active investigation tumors, including non–small cell lung cancer, colorectal HER2-low...

10.1080/14712598.2021.1890710 article EN cc-by-nc-nd Expert Opinion on Biological Therapy 2021-03-24

Contrary to common belief a single C–H⋯F–C contact in [(η5-C5H5)Pd(C6F5)(PPh3)] is strong enough pair two independent molecules and render them crystallographically different as suggested by its strongest 1H–19F dipole–dipole coupling 2-D CP/MAS PILGRIM NMR experiment together with solid state 1-D 19F{1H} 19F RFDR spectroscopy – thereby proving the power of solid-state for assessing strength supramolecular contacts.

10.1039/b610718b article EN CrystEngComm 2006-01-01

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTLiquid crystals based on ortho-palladated azines: nonplanar mesogensP. Espinet, E. Lalinde, M. Marcos, J. Perez, and L. SerranoCite this: Organometallics 1990, 9, 3, 555–560Publication Date (Print):March 1, 1990Publication History Published online1 May 2002Published inissue 1 March 1990https://pubs.acs.org/doi/10.1021/om00117a004https://doi.org/10.1021/om00117a004research-articleACS PublicationsRequest reuse permissionsArticle...

10.1021/om00117a004 article EN Organometallics 1990-03-01

The synthesis of mono- and dinuclear cyclometallated palladium(II) complexes with deprotonated saccharinate ligands displaying different coordination modes is described. new compounds were prepared by direct reaction between saccharine the corresponding hydroxo-complexes [{Pd(μ-OH)(C⁁N)}2] (C^N = 2-(2-pyridyl)phenyl (Phpy) I; 7,8-benzoquinolyl (Bzq) II), showing a general formula [{Pd(μ-sac)(C^N)}2] 1 bridging –NCO-coordination mode. Bridge splitting neutral (L pyridine (py) 2, quinoline...

10.1039/c2dt12187e article EN Dalton Transactions 2012-01-01

New cyclometalated palladium complexes of general formula [Pd(Bmim)(X)(C∧N)] have been synthesized by a novel reaction route involving di-μ-hydroxo-palladacycles [{Pd(μ-OH)(C∧N)}2] (C∧N = 2-benzoylpyridine (Bzpy), I, previously unreported, or C∧N 2-phenylpyridine (Phpy), II)] and 1,3-butylmethylimidazolium salts [HBmim]X (X: Cl, Br, saccharinate (Sacc); a, b, c, d complexes, respectively). This simple acid–base could not be achieved under identical conditions when corresponding di-μ-acetate...

10.1021/om501160n article EN Organometallics 2015-01-09

Mononuclear palladium hydroxo complexes of the type [Pd(N[bond]N)(C(6)F(5))(OH)] [(N[bond]N = 2,2'-bipyridine (bipy), 4,4'-dimethyl-2,2'-bipyridine (Me(2)bipy), 1,10-phenanthroline (phen), or N,N,N',N'-tetramethylethylenediamine (tmeda)] have been prepared by reaction [Pd(N[bond]N)(C(6)F(5))(acetone)]ClO(4) with KOH in methanol. These react, methanol, CO (1 atm, room temperature) to yield corresponding methoxycarbonyl [Pd(N[bond]N)(C(6)F(5))(CO(2)Me)]. Similar alkoxycarbonyl...

10.1021/ic0300058 article EN Inorganic Chemistry 2003-05-08
Coming Soon ...